*Corresponding author:
Kashif Aziz, Department of Medicine, Icahn School of Medicine Mount Sinai, Queens Hospital Center, Jamaica, New York, USAReceived: September 13, 2018; Published: September 26, 2018
DOI: 10.26717/BJSTR.2018.09.001792
To view the Full Article Peer-reviewed Article PDF
Aim: Hepatitis treatment with direct acting antivirals improves markers of diabetes like HbA1c and also decreases daily requirement of anti-diabetic medications.
Background: Insulin resistance and Type 2 diabetes are one of manifestation of Hepatitis C (HCV). It is proposed that circulating micro ribonucleic acid (miRNA) can do regulatory functions to modulate gene expression in peripheral tissues leading to insulin resistance and diabetes. Clearance of HCV with direct‐acting antivirals (DAAs) significantly decreases hemoglobin A1c (HbA1c) and the dependence on anti‐glycemic medications.
Case Description: we present a case of HCV positive diabetic patient treated with the combination of sofosbuvir/velpatasvir/voxilaprevir, lead to improvement of his HbA1c as well as significant reduction of his daily insulin dose.
Conclusion: It is concluded that treatment of HCV with DAAs may cause improvement of glucose metabolism and decreases dependence on anti-diabetic medications.
Keywords: Hepatitis C; Sofosbuvir or Velpatasvir or Voxilaprevir; Hba1c; Type 2 Diabetes; Direct Acting Antiviral Agents
Abbreviations: HbA1c: Hemoglobin A1c; DAAs: Direct Acting Antivirals; HCV: Hepatitis C Virus; miRNA: Micro Ribonucleic Acid; CHC: Chronic Hepatitis C Virus Infection; SOF: Sofosbuvir; LED: Ledipasvir; Low LDL: Density Lipoprotein; SVR: Sustained Virologic Response
Abstract | Background | Case Report| Discussion | Conclusion | Protection of Humans and Animals| Data Confidentiality | Patient Consent | References|